Belgium
About UCB SA
UCB SA is a global biopharmaceutical company dedicated to developing innovative products and solutions for individuals suffering from neurology and immunology diseases. Headquartered in Brussels, Belgium, the company was established in 1925 and has since been a leader in its field.
Key Products and Solutions
- Cimzia – Treats inflammatory TNF-mediated diseases, including ankylosing spondylitis (AS), Crohn's disease, and rheumatoid arthritis.
- Vimpat, Keppra, and Briviact – Medications for epilepsy management.
- Neupro – Used for Parkinson’s disease and restless legs syndrome.
- Nayzilam – A nasal spray rescue treatment for epilepsy seizure clusters.
- Zyrtec and Xyzal – Allergy relief medications.
- Evenity – Designed for osteoporosis treatment in postmenopausal women.
- Bimzelx – Targets plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
- Fintepla – Treats Dravet/Lennox-Gastaut syndrome.
- RYSTIGGO and ZILBRYSQ – Solutions for generalized myasthenia gravis.
Pipeline and Development
UCB SA is actively involved in research and development, with ongoing projects including:
- Doxecitine/Doxribtimine – For TK2 deficiency disorder.
- Fenfluramine – Targeting CDKL5 deficiency disorder.
- Dapirolizumab Pegol – For systemic lupus erythematosus.
- STACCATO Alprazolam – Treats stereotypical prolonged seizures.
- Bepranemab – A potential treatment for Alzheimer’s disease.
- UCB0222 – Focused on Parkinson’s disease.
- UCB9741 and UCB1381 – For atopic dermatitis.
Additional Activities
Beyond its core pharmaceutical offerings, UCB SA also engages in contract manufacturing, further expanding its impact in the healthcare industry.
